HUTCHMED (China) Limited

NasdaqGS:HCM Stock Report

Market Cap: US$3.2b

HUTCHMED (China) Management

Management criteria checks 4/4

HUTCHMED (China)'s CEO is Wei-Guo Su, appointed in Jan 2012, has a tenure of 12.75 years. total yearly compensation is $2.45M, comprised of 32.5% salary and 67.5% bonuses, including company stock and options. directly owns 0.49% of the company’s shares, worth $15.85M. The average tenure of the management team and the board of directors is 8.1 years and 7.6 years respectively.

Key information

Wei-Guo Su

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage32.5%
CEO tenure12.8yrs
CEO ownership0.5%
Management average tenure8.1yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Hutchmed Growing Sales By 64% In H1 2024

Aug 09

Hutchmed Is Turning Profitable

Mar 20

Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder

Oct 10

Hutchmed, Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004

Aug 09

Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype

Aug 01

Hutchmed begins dosing in early-stage study of cancer drug HMPL-A83

Jul 15

Hutchmed, Inmagene begin dosing in early-stage study of IMG-007 for eczema

Jul 06

Hutchmed Roils Markets With Changing Of Its Guard, U.S. Delisting Threat

Mar 11

CEO Compensation Analysis

How has Wei-Guo Su's remuneration changed compared to HUTCHMED (China)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

US$29m

Dec 31 2023US$2mUS$798k

US$101m

Sep 30 2023n/an/a

US$36m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$195m

Dec 31 2022US$4mUS$700k

-US$361m

Sep 30 2022n/an/a

-US$308m

Jun 30 2022n/an/a

-US$255m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$3mUS$395k

-US$195m

Sep 30 2021n/an/a

-US$187m

Jun 30 2021n/an/a

-US$178m

Mar 31 2021n/an/a

-US$151m

Dec 31 2020US$1mUS$346k

-US$126m

Sep 30 2020n/an/a

-US$117m

Jun 30 2020n/an/a

-US$110m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$1mUS$274k

-US$106m

Sep 30 2019n/an/a

-US$93m

Jun 30 2019n/an/a

-US$87m

Mar 31 2019n/an/a

-US$83m

Dec 31 2018US$1mUS$273k

-US$75m

Sep 30 2018n/an/a

-US$72m

Jun 30 2018n/an/a

-US$61m

Mar 31 2018n/an/a

-US$39m

Dec 31 2017US$2mUS$310k

-US$27m

Compensation vs Market: Wei-Guo's total compensation ($USD2.45M) is below average for companies of similar size in the US market ($USD6.65M).

Compensation vs Earnings: Wei-Guo's compensation has been consistent with company performance over the past year.

CEO

Wei-Guo Su (66 yo)

12.8yrs

Tenure

US$2,451,164

Compensation

Dr. Wei-Guo Su, B.Sc., Ph D., has been the Chief Executive Officer of HUTCHMED (China) Limited since March 04, 2022. Dr. Su has been the Chief Scientific Officer and Executive Vice President of HUTCHMED (C...

Leadership Team

NamePositionTenureCompensationOwnership
Wei-Guo Su
CEO, Chief Scientific Officer & Executive Director12.8yrsUS$2.45m0.49%
$ 15.9m
Chig Fung Cheng
CFO & Executive Director16.3yrsUS$962.15k0.18%
$ 5.9m
Edith Shih
Company Secretary & Non-Executive Director18.8yrsno datano data
Yiling Cui
Executive VP & Head of Operationsless than a yearno datano data
David Ng
Head of Investor Relations & Capital Strategiesno datano datano data
Charles George Rupert Nixon
Group General Counsel9.4yrsno datano data
Kin Hung Lee
Senior Vice President of Corporate Management & Communications1.8yrsno datano data
Selina Zhang
Senior Vice President of Global Human Resources2.8yrsno datano data
Qingmei Wang
Senior Vice President of Business Development & Strategic Alliancesno datano datano data
Hong Chen
Executive VP & Chief Commercial Officer- China6.8yrsno datano data
Zhenping Wu
Executive Vice President of Pharmaceutical Science & Manufacturing12.8yrsno datano data
Thomas Fu
Senior Vice President of Global Quality3.5yrsno datano data

8.1yrs

Average Tenure

59yo

Average Age

Experienced Management: HCM's management team is seasoned and experienced (8.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wei-Guo Su
CEO, Chief Scientific Officer & Executive Director7.6yrsUS$2.45m0.49%
$ 15.9m
Chig Fung Cheng
CFO & Executive Director13.8yrsUS$962.15k0.18%
$ 5.9m
Edith Shih
Company Secretary & Non-Executive Director18.8yrsno datano data
Dan Eldar
Non-Executive Chairman8.2yrsno data0.013%
$ 415.2k
Ling Yang
Non-Executive Director1.3yrsno datano data
Graeme Allan Jack
Independent Non-Executive Director7.6yrsUS$111.00k0.0053%
$ 172.8k
Paul Rutherford Carter
Senior Independent Non-Executive Director7.7yrsUS$117.00k0.0087%
$ 280.3k
Shu Kam Mok
Independent Non-Executive Director7yrsUS$114.86k0.011%
$ 362.1k
Renu Bhatia
Independent Non-Executive Directorless than a yearno datano data

7.6yrs

Average Tenure

65yo

Average Age

Experienced Board: HCM's board of directors are considered experienced (7.6 years average tenure).